No evidence of difference in mortality with amoxicillin versus co-amoxiclav for hospital treatment of community-acquired pneumonia

Current guidelines recommend broad-spectrum antibiotics for high-severity community-acquired pneumonia (CAP), potentially contributing to antimicrobial resistance (AMR). We aim to compare outcomes in CAP patients treated with amoxicillin (narrow-spectrum) versus co-amoxiclav (broad-spectrum), to understand if narrow-spectrum antibiotics could be used more widely.

Source: Journal of Infection - April 23, 2024 Category: Infectious Diseases Authors: Jia Wei, Aashna Uppal, Christy Nganjimi, Hermione Warr, Yasin Ibrahim, Qingze Gu, Hang Yuan, Najib M Rahman, Nicola Jones, A Sarah Walker, David W Eyre Source Type: research